Skip to content

Although hepatitis B reactivation is rare after a switch to injectable cabotegravir / rilpivirine, people with HIV require careful monitoring before and after a switch to assess protection against hepatitis B and reactivation risks, studies presented at last week’s International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026) suggest.

Cohort studies carried out in Spain and Italy found that rates of hepatitis B reactivation after switching to injectable cabotegravir / rilpivirine were low or non-existent. But the Italian study highlighted the risk of poor or non-existent immunity to hepatitis B despite vaccination. Three vaccinated people acquired hepatitis B during the study, although their infections were asymptomatic and detected only through tests for hepatitis B core antibody (anti-HBc) and surface antibody (anti-HBs).

People with active chronic hepatitis B are not recommended to switch away from HIV treatment regimens containing tenofovir, which also suppresses hepatitis B. But for a much larger group of people – those with past exposure to hepatitis B or potential hidden, low-level infection – the risks and benefits of switching away from tenofovir have been less clear.

Cohort studies in Europe report that approximately one-third of people with HIV have antibodies to hepatitis B core antigen (anti-HBc) but have no detectable hepatitis B surface antigen, showing that they have cleared hepatitis B infection or have a very low-level (occult) infection.

Reactivation of hepatitis B due to an occult infection after the withdrawal of tenofovir is rare; a meta-analysis of studies that carried out regular HBV testing after tenofovir withdrawal found that nearly four cases occurred in every 100 person-years of follow-up. In most cases they are detected only by testing, but a US Veterans study found that one in four reactivations were accompanied by a flare-up of hepatitis that may lead to hospitalisation and liver damage.

There seems to be no way to predict who will experience reactivation or how soon reactivation might occur after tenofovir withdrawal, emphasising the importance of regular monitoring for reactivation.

Although the risk of reactivation appears low when taking dolutegravir / lamivudine, the currently available evidence is not sufficient to confirm that lamivudine protects against reactivation, Professor Anna Maria Geretti of the Royal Free Hospital, London, told the conference.

More data is also needed on the risk of reactivation after switching to cabotegravir / rilpivirine. Two studies presented at HIV Glasgow provided further information. 

Glossary

antibody

A protein substance (immunoglobulin) produced by the immune system in response to a foreign organism. Many diagnostic tests for HIV detect the presence of antibodies to HIV in blood.

hepatitis

Inflammation of the liver, which can be caused by hepatitis viruses (A, B, C etc), alcohol or some drugs. If not treated, hepatitis can lead to hepatic fibrosis and/or cirrhosis.

HIV

Human immunodeficiency virus, the virus which causes AIDS. There are two variants: HIV-1, and HIV-2. HIV-1 is by far the most common worldwide. See ‘subtype’ for more information.

on

Abbreviation of a Latin term meaning every night.

therapy

Any form of treatment. Drugs, radiation, and psychiatric counselling are forms of therapy. 

In Spain, the RELATIVITY cohort followed 3349 people who switched to cabotegravir / rilpivirine before the end of 2024. Participants were followed for a median of 25 months after switching. The cohort was predominantly male (84%) and had been taking antiretroviral therapy for a median of nine years before switching.

Half of all participants had been vaccinated against hepatitis B and had immunity, defined as testing positive for hepatitis B surface antibody and negative for hepatitis B core antibody. A further 12% had been vaccinated but did not have immunity. Seven percent had not been vaccinated and did not have evidence of exposure (no antibodies to HBc or HBs).

Twelve per cent of participants had evidence of past HBV infection (anti-HBc and anti-HBs) while 3% had isolated anti-HBc without surface antibody, indicating either waning infection or extremely low-level HBV infection. Five study participants had active HBV (detectable hepatitis B surface antigen) at study entry. HBV serology was unavailable for 13% of participants.

HBV serology was carried out during follow-up if acute infection was suspected but it was not carried out routinely for all participants.

Isolated anti-HBc was detected in 115 people during a median 25 months of follow-up. No cases of clinically suspected reactivation with liver enzyme elevations were observed. Thirteen people had ALT increases but HBsAg was negative. HBV DNA testing was not done in all people with isolated anti-HBc so reactivation may be underestimated, Dr Luz Martin Carbonero of University Hospital La Paz, Madrid, noted.

One person who had been vaccinated twice without developing antibody responses to hepatitis B acquired hepatitis B during the follow-up period.

In Italy, the SCohoLART study followed 627 people who switched to injectable cabotegravir / rilpivirine, for a median of 2.7 years.

Of these, 30% had previous HBV exposure, including 3% with isolated anti-HBc. Of the remainder, 50% had vaccine-induced immunity and 19% had no previous exposure or immunity.

During the follow-up period, four people experienced HBV-related events. One participant with anti-HBc at the time of switching developed symptomatic reactivation of hepatitis B within three months of switching, leading to hospitalisation and resumption of tenofovir-containing treatment.

Three vaccinated participants who were anti-HBc negative at the time of switching were found to have acquired HBV during follow-up. Two had no immunity despite vaccination; one had been vaccinated but had low levels of anti-HBs. HBV acquisition was detected by routine HBV serology.

The findings underline the importance of checking immunisation status and antibody levels before switching to cabotegravir / rilpivirine or another regimen that doesn’t contain an HBV-active antiretroviral. 

Professor Anna Maria Geretti said that forthcoming British HIV Association guidelines will recommend the following management protocol for people with isolated anti-HBc measurements before switching:

  • If anti-HBc positive but HBsAg-negative and HBV-DNA negative, give one dose of HBV vaccine and test for anti-HBs two weeks later.
  • If anti-HBs levels are above 10 IU/ml, evaluate other risk factors for reactivation before switching.
  • If anti-HBs levels are below 10 IU/ml, complete the HBV vaccine series before evaluating risk factors and before switching.

Professor Geretti emphasised that although immunisation is advisable, inducing or boosting anti-HBs has not been shown to protect against reactivation, so it is important to assess the reactivation risk before switching.

Re-vaccination is also advisable for people without anti-HBs, especially in circumstances where vaccination history is missing. A cross-sectional study of 679 people receiving HIV care in Buenos Aires, Argentina, found that information on HBV status was missing in over 40% of participants and 30% lacked protective immunity to HBV, either due to absence of vaccination or waning protection.

 

ConferenceHIV Glasgow 2026
Date8-11 November
LocationGlasgow, UK & online

References

Geretti AM. Hepatitis B 2-drug regimen and re-activation. International Congress on Drug Therapy in HIV Infection, Glasgow, 2026.

Rueda MMA et al. HBV outcomes after switching to long-acting cabotegravir plus rilpivirine in the Spanish RELATIVITY cohort. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract O35, 2026.

Raccagni AR et al. Hepatitis B after switch to long-acting cabotegravir / rilpivirine: data from the SCohoLART study. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract O36, 2026.

Laufer N et al. Incomplete HBV serological documentation could mask unrecognized immunity gaps in people living with HIV receiving tenofovir-sparing antiretroviral therapy. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P505, 2026.

Keith Alcorn

Keith Alcorn

Editorial Consultant

Keith joined the editorial team of the National AIDS Manual (NAM) in 1991, launched the aidsmap website in 1998 and was the Senior Editor of NAM and aidsmap until 2018. He now contributes news and conference reports as a freelancer.

More news

Hepatitis B reactivation is rare after switching from tenofovir, two European studies show

Dr Alberto Foncillas presenting the Barcelona study at EACS 2025. He is speaking at a podium in front of a screen.

Injectable HIV treatment works for people with poor HIV control in Africa

Dr Fiona Cresswell at IAS 2025. She is wearing a red top and has brown hair. She is talking into a microphone behind a podium.

Injectable HIV treatment does as well as daily pills in real-world settings

Dr Alisa Timiryasova at HIV Glasgow 2026. She is standing behind a lectern, with a screen behind her.